Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating Costs and Expenses:
General and administrative	$ 4,580	$ 5,727
Research and development	11,083	11,844
Total Operating Costs and Expenses	15,663	17,571
Loss from Operations	(15,663)	(17,571)
Other Income :
Change in fair value of warrant liability	0	4,083
Interest income	283	67
Total Other Income	283	4,150
Net Loss	(15,380)	(13,421)
Net Loss Attributable to Non-controlling Interest	(77)	(54)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	(15,303)	(13,367)
Preferred Stock Dividends, Income Statement Impact	(248)	(243)
Net Loss Attributable to Common Stockholders	$ (16,076)	$ (25,291)
Net Loss Per Share - Basic and Dilutive	$ (0.98)	$ (4.06)
Weighted average number of shares outstanding during the period - Basic and Dilutive	16,438,201	6,232,442
Series A Preferred Stock [Member]
Other Income :
Preferred Stock Dividends, Income Statement Impact	$ (248)	$ (243)
Series B Preferred Stock [Member]
Other Income :
Net Loss Attributable to Non-controlling Interest	0	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	0	0
Preferred Stock Dividends, Income Statement Impact	$ (525)	$ (11,681)